Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4
Nitrendipine is prescribed to children for the treatment of primary hypertension (off-label use). Available specialties (Nidrel®, Baypress® and others generic drugs) are only marketed in tablet form, which is unsuitable for pediatric use. A hospital preparation of nitrendipine oral suspension at 5 m...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2018-03-01
|
| Series: | Pharmaceutical Technology in Hospital Pharmacy |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/pthp-2017-0030 |
| _version_ | 1818689836269174784 |
|---|---|
| author | Bellay Romain Bonnaure Anne-Claire Rault Pauline Pertuisel Sophie Lester Marie-Antoinette Boivin Pierre-Nicolas |
| author_facet | Bellay Romain Bonnaure Anne-Claire Rault Pauline Pertuisel Sophie Lester Marie-Antoinette Boivin Pierre-Nicolas |
| author_sort | Bellay Romain |
| collection | DOAJ |
| description | Nitrendipine is prescribed to children for the treatment of primary hypertension (off-label use). Available specialties (Nidrel®, Baypress® and others generic drugs) are only marketed in tablet form, which is unsuitable for pediatric use. A hospital preparation of nitrendipine oral suspension at 5 mg/mL was developed. The aim of the study was to determine physicochemical and microbiological stability of the nitrendipine oral suspension in order to set a shelf life for the preparation. |
| first_indexed | 2024-12-17T12:16:26Z |
| format | Article |
| id | doaj.art-bbb98bb993754d93a61cb2248c6e52ec |
| institution | Directory Open Access Journal |
| issn | 2365-2411 2365-242X |
| language | English |
| last_indexed | 2024-12-17T12:16:26Z |
| publishDate | 2018-03-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Pharmaceutical Technology in Hospital Pharmacy |
| spelling | doaj.art-bbb98bb993754d93a61cb2248c6e52ec2022-12-21T21:49:10ZengDe GruyterPharmaceutical Technology in Hospital Pharmacy2365-24112365-242X2018-03-0131313710.1515/pthp-2017-0030Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4Bellay Romain0Bonnaure Anne-Claire1Rault Pauline2Pertuisel Sophie3Lester Marie-Antoinette4Boivin Pierre-Nicolas5Pharmacy, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FrancePharmacy, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FrancePharmacy, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FrancePediatric Oncology, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FrancePharmacy, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FrancePharmacy, CHU de Rennes, 2 rue Henri Le Guilloux, 35000Rennes, FranceNitrendipine is prescribed to children for the treatment of primary hypertension (off-label use). Available specialties (Nidrel®, Baypress® and others generic drugs) are only marketed in tablet form, which is unsuitable for pediatric use. A hospital preparation of nitrendipine oral suspension at 5 mg/mL was developed. The aim of the study was to determine physicochemical and microbiological stability of the nitrendipine oral suspension in order to set a shelf life for the preparation.https://doi.org/10.1515/pthp-2017-0030pediatricshypertensioncalcium-channel blockersstabilityhplc |
| spellingShingle | Bellay Romain Bonnaure Anne-Claire Rault Pauline Pertuisel Sophie Lester Marie-Antoinette Boivin Pierre-Nicolas Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 Pharmaceutical Technology in Hospital Pharmacy pediatrics hypertension calcium-channel blockers stability hplc |
| title | Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 |
| title_full | Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 |
| title_fullStr | Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 |
| title_full_unstemmed | Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 |
| title_short | Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4 |
| title_sort | stability of 5 mg ml nitrendipine oral suspension in syrspend r sf ph4 |
| topic | pediatrics hypertension calcium-channel blockers stability hplc |
| url | https://doi.org/10.1515/pthp-2017-0030 |
| work_keys_str_mv | AT bellayromain stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 AT bonnaureanneclaire stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 AT raultpauline stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 AT pertuiselsophie stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 AT lestermarieantoinette stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 AT boivinpierrenicolas stabilityof5mgmlnitrendipineoralsuspensioninsyrspendsfph4 |